NEW YORK (GenomeWeb News) – Bruker today said that revenues for its fourth quarter rose 9 percent year over year, and it beat the average analyst estimates on the top and bottom lines.

Despite the strong finish to the year, a company official said on a conference call following the release of the results that restructuring initiatives are expected to result in layoffs this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.